Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 22, Issue 4, Pages 463-486
Publisher
Informa Healthcare
Online
2013-03-02
DOI
10.1517/13543784.2013.774372
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
- (2013) John P.H. Wilding ANNALS OF INTERNAL MEDICINE
- Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
- (2013) Stephan A. Veltkamp et al. CLINICAL DRUG INVESTIGATION
- Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
- (2013) Muhammad Abdul-Ghani et al. Endocrine Practice
- Regulation of the human Na+-dependent glucose cotransporter hSGLT2
- (2012) Chiara Ghezzi et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences
- (2012) Ivan Sabolić et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial
- (2012) B Zambrowicz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study
- (2012) L.E. Nicolle et al. CURRENT MEDICAL RESEARCH AND OPINION
- Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor
- (2012) Paul Nyirjesy et al. CURRENT MEDICAL RESEARCH AND OPINION
- Damaging Loss of Self-Control by Stressed -Cells
- (2012) M. J. Holness et al. DIABETES
- Why Do SGLT2 Inhibitors Inhibit Only 30-50% of Renal Glucose Reabsorption in Humans?
- (2012) J. Liu et al. DIABETES
- Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
- (2012) J. Rosenstock et al. DIABETES CARE
- Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus
- (2012) G. Luippold et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
- (2012) R. R. Henry et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Comparison of demographic factors and cardiovascular risk factor control among U.S. adults with type 2 diabetes by insulin treatment classification
- (2012) Kalina Wong et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database
- (2012) Ishan Hirji et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)
- (2012) Ishan Hirji et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- (2012) Yoshihito Ohtake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats
- (2012) James J. Devenny et al. Obesity
- Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
- (2012) Yin Liang et al. PLoS One
- Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
- (2012) Jean Whaley et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Relative Expression of a Dominant Mutated ABCC8 Allele Determines the Clinical Manifestation of Congenital Hyperinsulinism
- (2011) R. Shemer et al. DIABETES
- Na+-D-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion
- (2011) V. Gorboulev et al. DIABETES
- SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
- (2011) Michael J. Jurczak et al. DIABETES
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
- (2011) M. A. Nauck et al. DIABETES CARE
- Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
- (2011) L. Thomas et al. DIABETES OBESITY & METABOLISM
- Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients
- (2011) R. L. Dobbins et al. DIABETES OBESITY & METABOLISM
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
- (2011) K. Strojek et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus
- (2011) A. S. Kalgutkar et al. DRUG METABOLISM AND DISPOSITION
- Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors
- (2011) Vincent Mascitti et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Sweet Pee Model for Sglt2 Mutation
- (2011) J. P. Ly et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
- (2011) Atsuo Tahara et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats
- (2011) Wenbin Zhang et al. PHARMACOLOGICAL RESEARCH
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats
- (2010) F. R. Macdonald et al. DIABETES OBESITY & METABOLISM
- Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study
- (2010) Elizabeth K. Hussey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
- (2010) Elizabeth K. Hussey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of Canagliflozin, a NovelC-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus(1)
- (2010) Sumihiro Nomura et al. JOURNAL OF MEDICINAL CHEMISTRY
- (1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment
- (2010) Hiroyuki Kakinuma et al. JOURNAL OF MEDICINAL CHEMISTRY
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
- (2010) V. Vallon et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- SGLT2 inhibition — a novel strategy for diabetes treatment
- (2010) Edward C. Chao et al. NATURE REVIEWS DRUG DISCOVERY
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
- (2010) Jian Chen et al. Diabetes Therapy
- Glucose Control by the Kidney: An Emerging Target in Diabetes
- (2009) Olivera Marsenic AMERICAN JOURNAL OF KIDNEY DISEASES
- Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target
- (2009) R. Santer et al. Clinical Journal of the American Society of Nephrology
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats
- (2009) Horacio Osorio et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Development of the Renal Glucose Reabsorption Inhibitors: A New Mechanism for the Pharmacotherapy of Diabetes Mellitus Type 2
- (2009) William N. Washburn JOURNAL OF MEDICINAL CHEMISTRY
- Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
- (2008) S. Han et al. DIABETES
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
- Enhanced expressions of sodium–glucose cotransporters in the kidneys of diabetic Zucker rats
- (2008) Niloofar M. Tabatabai et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes
- (2008) S. A. Jabbour et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- (2008) Wei Meng et al. JOURNAL OF MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now